12 Results for "

IBT

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "IBT" in MCE Product Catalog:

Cat. No.: HY-13036A
CAS No.: 1022150-12-4
Purity:  99.59%
Target:  

Btk

Research Areas:  

Cancer

IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-78727
CAS No.: 330786-24-8
Synonyms: IBT4A
Target:  

Drug Intermediate Btk

Research Areas:  

Inflammation/Immunology Cancer

Ibrutinib deacryloylpiperidine (IBT4A) is a derivative of an Ibrutinib (HY-10997) intermediate and an Ibrutinib impurity. Ibrutinib deacryloylpiperidine serves as a starting material and is used in the synthesis of a modified BTK inhibitor derivative via the Mitsunobu reaction .
loading...
    loading...
Cat. No.: HY-16660
CAS No.: 313553-47-8
Synonyms: IBT13131
Target:  

NEKs Apoptosis

Research Areas:  

Cancer

INH1 specifically disrupts the Hec1/Nek2 interaction via direct Hec1 binding. INH1 shows promising cancer inhibition activity both in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-W291131
CAS No.: 27830-79-1
Synonyms: IBT
Target:  

HSV Orthopoxvirus

Research Areas:  

Infection

Isatin-β-thiosemicarbazone is a potent anti-poxvirus agent (including monkeypox virus, orthopoxvirus, vaccinia virus, etc). Isatin-β-thiosemicarbazone also is a potent herpes simplex virus (HSV) inhibitor. Isatin-β-thiosemicarbazone exhibits
loading...
    loading...
Cat. No.: HY-13036
CAS No.: 1412418-47-3
Purity:  98.18%
Target:  

Btk

Research Areas:  

Cancer

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-13036B
CAS No.: 1553977-42-6
Purity:  99.72%
Target:  

Btk

Research Areas:  

Cancer

IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-13036C
CAS No.: 1807619-60-8
Target:  

Btk

Research Areas:  

Cancer

(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM .
loading...
    loading...
Cat. No.: HY-163963
CAS No.: 1970122-88-3
Research Areas:  

Cancer

IBT6A-CO-ethyne is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). IBT6A-CO-ethyne can be used for synthesis IBT6A (HY-13036A) .
loading...
    loading...
Cat. No.: HY-W591307
CAS No.: 2360561-66-4
Target:  

PROTAC Linkers

Research Areas:  

Cancer

P131 is a PROTAC molecule comprised of Pomalidomide-based cereblon ligand and IBT6A, linked by a PEG 3 chain. P131 can degrade both wild-type and C481S mutant BTK with nanomolar potencies.
loading...
    loading...
Cat. No.: HY-134800
CAS No.: 692744-81-3
Target:  

ATF6 IRE1 PERK

Research Areas:  

Infection

IBT21 is an endoplasmic reticulum stress inhibitor that binds to unfolded or misfolded proteins and prevents their aggregation. IBT21 inhibits UPR activation of the ATF6, IRE1 and PERK branches under ER stress, with IC50 values of 0.24 μM, 0.33 μM, and 0.46 μM, respectively. IBT21 protects cells from ER stress-induced death and mutant prion protein (protein toxin)-induced growth inhibition. IBT21 exhibits chemical chaperone activity distinct from UPR modulators, does not affect protein translation, moderately reduces DTT (HY-15917)-induced ER stress, and fails to inhibit the heat shock response. IBT21 is useful for research related to prion diseases .
loading...
    loading...
Cat. No.: HY-181546
Target:  

Btk PERK Syk HMG Family

Research Areas:  

Cancer

Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .
loading...
    loading...
Cat. No.: HY-W017180
CAS No.: 72707-66-5
Synonyms: α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA
Target:  

Drug Intermediate

Research Areas:  

Cancer

2-(Bromomethyl) acrylic acid (α-MAA) is a component of Ibt-DOX (HY-181546) .
loading...
    loading...
  • 1